From: Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
p value | ||||||
---|---|---|---|---|---|---|
Controls | MCI | AD | Controls–MCI | Controls–AD | MCI–AD | |
Norwegian cohort | n = 50 | n = 21 | n = 29 | |||
Gender | ||||||
Women | 25 | 12 | 13 | |||
Men | 25 | 9 | 16 | |||
Age | 66 (50–86) | 67 (55–75) | 68 (56–75) | |||
MMSE | 29 (29–30) | 27 (26–29) | 20 (17–24) | * | * | * |
CSF Aβ42 (pg/ml) | 1010 (880–1188) | 494 (356–531) | 500 (386–553) | * | * | 0.43 |
CSF T-tau (pg/ml) | 307 (201–391) | 628 (497–927) | 772 (647–1143) | * | * | 0.06 |
CSF P-tau (pg/ml) | 51 (38–61) | 75 (62–111) | 72 (67–91) | * | * | 1.00 |
ApoE genotype | ||||||
E2/E3 | 8 | – | 1 | |||
E2/E4 | – | 1 | ||||
E3/E3 | 35 | 5 | 5 | |||
E3/E4 | 6 | 8 | 12 | |||
E4/E4 | – | 8 | 10 | |||
Not known | 1 | |||||
CSF sTREM2 (ng/ml) | 4.4 (3.0–5.7) | 4.1 (2.4–5.9) | 4.8 (3.5–7.1) | 0.42 | 0.17 | 0.11 |
Swedish cohort | n = 25 | n = 25 | ||||
Gender | ||||||
Women | 17 | 18 | ||||
Men | 8 | 7 | ||||
Age | 62 (43–80) | 79 (61–86) | ||||
MMSE | 29 (28–30) | 18 (13–22) | * | |||
CSF Aβ42 (pg/ml) | 520 (469–597) | 340 (265–430) | * | |||
CSF T-tau (pg/ml) | 380 (233–480) | 670 (490–895) | * | |||
CSF P-tau (pg/ml) | 44 (36–61) | 80 (69–96) | * | |||
ApoE genotype | ||||||
E2/E3 | 5 | 1 | ||||
E2/E4 | 1 | 1 | ||||
E3/E3 | 14 | 4 | ||||
E3/E4 | 4 | 15 | ||||
E4/E4 | 1 | 4 | ||||
CSF sTREM2 (ng/ml) | 3.2 (2.8–5.0) | 3.8 (2.6–5.6) | 0.76 |